<DOC>
	<DOCNO>NCT03075644</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate safety weekly dosing somapacitan ( NNC0195-0092 ) daily Norditropin速 FlexPro速 52 week previously human growth hormone treat Japanese adult growth hormone deficiency .</brief_summary>
	<brief_title>A Trial Evaluate Safety Once Weekly Dosing Somapacitan ( NNC0195-0092 ) Daily Norditropin速 FlexPro速 52 Weeks Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female least 18 year age 79 year age time sign informed consent GHD diagnose least 6 month ( define 180 day ) prior screen Treatment hGH least 6 consecutive month ( define 180 day ) screen If applicable , hormone replacement therapy hormone deficiency , adequate stable least 90 day prior randomisation judge investigator Active malignant disease history malignancy . Exceptions exclusion criterion:1/ Resected situ carcinoma cervix squamous cell basal cell carcinoma skin complete local excision 2/ Subjects GHD attribute treatment intracranial malignant tumour leukaemia , provide recurrencefree survival period least 5 year document subject 's medical record For subject surgical removal debulking pituitary adenoma benign intracranial tumour within last 5 year : Evidence growth pituitary adenoma benign intracranial tumour within last 12 month ( define equal 365 day ) randomisation . Absence growth must document two postsurgery magnetic resonance imaging ( MRI ) scan CT scan . The recent MRI CT scan must perform equal 9 month ( define equal 270 day ) prior randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>